Biohaven shares are trading higher after HC Wainwright & Co maintained a Buy rating and raised its price target from $50 to $63.
Portfolio Pulse from Benzinga Newsdesk
Biohaven's stock price increased following an upgrade by HC Wainwright & Co, which maintained a Buy rating and raised its price target from $50 to $63.
March 04, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biohaven's stock price is likely to experience a short-term increase following the positive analyst rating and raised price target from HC Wainwright & Co.
Analyst ratings and price target adjustments are significant indicators of a stock's potential performance. The upgrade from HC Wainwright & Co, a reputable financial firm, suggests a strong confidence in Biohaven's future prospects, likely leading to increased investor interest and a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90